Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | PBK | Q96KB5 | 6/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 8/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | CDK2AP1 | O14519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21225769 | 1.00 | SYK (0.49) | SYKMLLT1MAPK1OPRK1PBK | |
| SCHEMBL21225379 | 1.00 | SYK (0.49) | SYKMLLT1MAPK1OPRK1PBK | |
| SCHEMBL21225618 | 0.93 | SYK (0.43) | SYKMLLT1PBK | |
| SCHEMBL21225620 | 0.93 | SYK (0.43) | SYKMLLT1PBK | |
| SCHEMBL21225690 | 0.93 | SYK (0.43) | SYKMLLT1PBK | |
| SCHEMBL21225682 | 0.88 | MLLT1 (0.41) | SYKMLLT1 | |
| SCHEMBL29990642 | 0.88 | MLLT1 (0.41) | SYKMLLT1 | |
| SCHEMBL25531945 | 0.83 | SYK (0.41) | SYKMLLT1PBKCCNA2CDK2 | |
| SCHEMBL25531884 | 0.83 | SYK (0.41) | SYKMLLT1PBK | |
| SCHEMBL21225574 | 0.81 | TAS1R3 (0.38) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018033-B2 | Inhibitors of protein arginine deiminases | FORWARD THERAPEUTICS, INC. (US) | 2024-06-25 | — | — | US | claimed |
| US-11453676-B2 | Inhibitors of protein arginine deiminases | FORWARD THERAPEUTICS, INC. (US) | 2022-09-27 | — | — | US | claimed |
| US-20210053975-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | FORWARD THERAPEUTICS, INC. | 2021-02-25 | — | — | US | claimed |
| EP-3746430-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | Padforward LLC (US) | 2020-12-09 | — | — | EP | claimed |
| WO-2019152883-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | PADFORWARD LLC (US) | 2019-08-08 | — | — | WO | claimed |
| US-12018033-B2 | Inhibitors of protein arginine deiminases | FORWARD THERAPEUTICS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230151018-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | FORWARD THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151018-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | FORWARD THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151018-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | FORWARD THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-11453676-B2 | Inhibitors of protein arginine deiminases | FORWARD THERAPEUTICS, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-20210053975-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | FORWARD THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20210053975-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | FORWARD THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
| WO-2019152883-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | PADFORWARD LLC (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151018-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | PADI2, PADI1, PADI4 | SYK 2709/4885MLLT1 858/4885MAPK1 2912/4885 |
| US-11453676-B2 | Inhibitors of protein arginine deiminases | PADI2, PADI1, PADI4 | SYK 2693/4885MLLT1 987/4885MAPK1 2197/4885 |
| US-20210053975-A1 | INHIBITORS OF PROTEIN ARGININE DEIMINASES | PADI2, PADI1, PADI4 | SYK 2709/4885MLLT1 858/4885MAPK1 2912/4885 |
| US-12018033-B2 | Inhibitors of protein arginine deiminases | PADI2, PADI1, PADI4 | SYK 2547/4885MLLT1 1129/4885MAPK1 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.